Skip to content

Mannkind Corp

MNKD· NasdaqCore metricsCIK 899460

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -0.60%
Market cap
$1.34B
321.64M shares
Filings
1,032
$101.87M
Q3 2026+22.2% FY25 yoy
-$23.22M
Q3 2026−78.7% FY25 yoy
-$2.18M
Q3 2026−46.5% FY25 yoy
-$68.45M
Q3 2026derived−58.3% FY25 yoy
-$0.07
Q3 2026−80.0% FY25 yoy
$41.28M
Q3 2026+61.6% FY25 yoy
$1.34B
—
3.2×
—
-5.87%
—

Twelve months to Sep 30, 2026 · derived

Price

$4.1620.86%$1.09past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$348.97MFY 2025
$348.97M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$348,966,000reported
FY 20242024-12-31$285,504,000reported
FY 20232023-12-31$198,962,000reported
FY 20222022-12-31$99,770,000reported
FY 20212021-12-31$75,442,000reported
FY 20202020-12-31$65,144,000reported
FY 20192019-12-31$63,038,000reported
FY 20182018-12-31$27,859,000reported
FY 20172017-12-31$11,745,000reported
FY 20162016-12-31$174,758,000reported
FY 20152015-12-31$0reported
FY 20142014-12-31$0reported

Segments

Products
Revenue by Products, FY2019 to FY2025FY2019AFREZZA product sales · FY2019 · $25.30MCollaborations and services · FY2019 · $37.73MFY2020AFREZZA product sales · FY2020 · $32.32MCollaborations and services · FY2020 · $32.82MServices · FY2020 · $32.82MProduct Sales · FY2020 · $32.32MFY2021Product Revenue · FY2021 · $39.44MAFREZZA product sales · FY2021 · $39.17MCollaborations and services · FY2021 · $36.27MServices · FY2021 · $36.01MProduct Sales · FY2021 · $39.44MFY2022Product Revenue · FY2022 · $81.07MRoyalties · FY2022 · $15.60MAFREZZA product sales · FY2022 · $56.25MCollaborations and services · FY2022 · $27.92MServices · FY2022 · $3.10MProduct Sales · FY2022 · $81.07MFY2023Product Revenue · FY2023 · $126.05MRoyalties · FY2023 · $71.98MAFREZZA product sales · FY2023 · $74.03MCollaborations and services · FY2023 · $52.95MServices · FY2023 · $929.00KFY2024Product Revenue · FY2024 · $178.56MRoyalties · FY2024 · $102.34MAFREZZA product sales · FY2024 · $82.33MCollaborations and services · FY2024 · $100.84MServices · FY2024 · $4.61MManufacturing Services · FY2024 · $7.10MFY2025Product Revenue · FY2025 · $216.52MRoyalties · FY2025 · $128.12MAFREZZA product sales · FY2025 · $114.14MCollaborations and services · FY2025 · $106.71MServices · FY2025 · $4.33MManufacturing Services · FY2025 · $1.60M
LineFY2025ShareChange
Product Revenue$216.52M62%+21.3%
Royalties$128.12M37%+25.2%
AFREZZA product sales$114.14M33%+38.6%
Collaborations and services$106.71M31%+5.8%
Services$4.33M1.2%−6.2%
Manufacturing Services$1.60M0.5%−77.5%
Product Sales———
Total$348.97M

From the 10-K filed Feb 26, 2026MNKD

Pharmaceutical preparations

Mannkind Corp is the 65th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Mannkind Corp · CIK 899460 · Engraved from SEC EDGAR